Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-21. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Pipeline trial failures in pelacarsen and eplontersen reduce projected peak risk-adjusted royalty cash flows, driving a 40% equity market cap reduction across IONS shares.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factIonis Pharmaceuticals shares have declined by more than 40% year-to-date. |
| What else was confirmed? | Reported factThe sell-off follows clinical trial setbacks in its late-stage pelacarsen and eplontersen pipeline programs. |
| Does the valuation support acting? | Interpretation4 stored valuation assumptions for IONS; the latest is dated 2026-09-23. |
| What would change the assessment? | UnknownPelacarsen regulatory and trial design update — Monitor partnership disclosures for revised trial timelines and FDA submission schedules. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Ionis Pharmaceuticals shares have declined by more than 40% year-to-date.
- · The sell-off follows clinical trial setbacks in its late-stage pelacarsen and eplontersen pipeline programs.
- · Consolidated Wall Street analyst price targets average $83.82, anchored by the firm's broader antisense oligonucleotide platform and commercial partnerships.
Public research record
Research framework · page evidenceCompleted event assessment
clinical pipeline delay and peak sales cash-flow discounting
| Type | Claim | Scope |
|---|---|---|
| Assumption | Ionis Pharmaceuticals shares have declined by more than 40% year-to-date. | 2026-09-21 |
| Interpretation | clinical pipeline delay and peak sales cash-flow discounting | IONS |
Countercase, invalidators, and sources
Subsequent pipeline readout data or partnered milestone payments stabilize the cash runway and narrow the discount to analyst targets.
- · Pelacarsen regulatory and trial design update — Monitor partnership disclosures for revised trial timelines and FDA submission schedules.
- Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook · 2026-09-20
What remains unresolved
- Base path
- Ionis equity consolidates at depressed valuations while markets await formal trial restructuring updates.
- Adverse path
- Additional pipeline failures or partner opt-outs trigger further write-downs of development assets.
- Supportive path
- Subsequent pipeline readout data or partnered milestone payments stabilize the cash runway and narrow the discount to analyst targets.
- · Pelacarsen regulatory and trial design update — Monitor partnership disclosures for revised trial timelines and FDA submission schedules.this week
Evidence
- Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook2026-09-20
“Ionis Pharmaceuticals stock has plummeted over 40% this year due to late-stage clinical trial failures and ongoing losses, yet Wall Street analysts maintain a bullish outlook with an average price target of $83.82.”
Supports: Ionis stock dropped over 40% following setbacks in pelacarsen and eplontersen trials.